IN8bio (MUN:6JH) - Hisse Senedi Fiyatı, Haberler ve Analizler

6JH Stoklara Genel Bakış

A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors.

Şirket hakkında

6JH temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Risk Analizi

Kazançlar son 5 yılda yılda 47% oranında azaldı

Geliri 1 milyon ABD dolarından az ( $0 )

Hisse senetleri oldukça likit değildir

Anlamlı bir piyasa değeri yok ( €37M )

+ 1 daha fazla risk

IN8bio, Inc. Rakipler

Medigene

XTRA:MDG1

€25.0m

2invest

XTRA:2INV

€59.8m

4SC

DB:VSC

€61.5m

Heidelberg Pharma

XTRA:HPHA

€111.9m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti IN8bio
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$2.78
52 Haftanın En Yüksek Seviyesi	US$6.13
52 Haftanın En Düşük Seviyesi	US$1.96
Beta	0
11 Aylık Değişim	0%
3 Aylık Değişim	-7.33%
1 Yıllık Değişim	-50.24%
33 Yıllık Değişim	n/a
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-66.83%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	6JH	DE Biotechs	DE Pazar
7D	0%	0.5%	-1.4%
1Y	-50.2%	-16.2%	11.8%

Getiri vs. Endüstri: 6JH geçen yıl % -16.2 oranında getiri sağlayan German Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: 6JH geçen yıl % 11.8 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 6JH's price volatile compared to industry and market?
6JH volatility
6JH Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.3%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: 6JH son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: 6JH 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2016	26	Will Ho	in8bio.com

IN8bio, Inc. Temel Bilgiler Özeti

IN8bio'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
6JH temel i̇stati̇sti̇kler
Piyasa değeri	€35.54m
Kazançlar(TTM)	-€25.70m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-1.4x

F/K Oranı

6JH aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
6JH gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$26.57m
Kazançlar	-US$26.57m

Son Raporlanan Kazançlar

Sep 30, 2022

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.08
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

6JH uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

6JH Stoklara Genel Bakış

Ödüller

Risk Analizi

IN8bio, Inc. Rakipler

XTRA:MDG1

€25.0m

XTRA:2INV

€59.8m

DB:VSC

€61.5m

XTRA:HPHA

€111.9m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

IN8bio, Inc. announced that it expects to receive $12.405547 million in funding

IN8bio, Inc. Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

IN8bio, Inc. Announces Updated Positive Clinical Data from Both of the Phase 1 Investigator-Sponsored Trials of INB-100 for Hematological Malignancies and INB-200 for GBM

IN8bio, Inc. Presents Positive Data Demonstrating Durable 1-Year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

IN8bio, Inc. Presents Progression-Free Survival Update from Phase 1 Study of INB-200 At 2024 American Society of Clinical Oncology Annual Meeting

In8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation At Asgct 2024

Recent updates

IN8bio, Inc. announced that it expects to receive $12.405547 million in funding

IN8bio, Inc. Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

IN8bio, Inc. Announces Updated Positive Clinical Data from Both of the Phase 1 Investigator-Sponsored Trials of INB-100 for Hematological Malignancies and INB-200 for GBM

IN8bio, Inc. Presents Positive Data Demonstrating Durable 1-Year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

IN8bio, Inc. Presents Progression-Free Survival Update from Phase 1 Study of INB-200 At 2024 American Society of Clinical Oncology Annual Meeting

In8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation At Asgct 2024

In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma

IN8bio, Inc., Annual General Meeting, Jun 12, 2024

IN8bio, Inc. Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

IN8bio, Inc. to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

IN8bio, Inc. announced that it has received $14.442298 million in funding from Bios Equity Partners LP

IN8bio, Inc. announced that it expects to receive $14.442298 million in funding

IN8bio, Inc. Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

IN8bio, Inc. Appoints Corinne Epperly to the Board of Directors

IN8bio, Inc.’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

IN8bio, Inc. Presents Biologic Correlative Data from the Inb-200 Phase 1 Trial in Newly Diagnosed Glioblastoma At the Society for Immunotherapy of Cancer's 38Th Annual Meeting

IN8bio, Inc. Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma

IN8bio, Inc. Announces Presentations at the Society for Immunology of Cancer 38th Annual Meeting

IN8bio, Inc. Announces Updated Data from the Ongoing Phase 1 Clinical Trial of Inb-200 in Patients with Newly Diagnosed Glioblastoma Multiforme

IN8bio, Inc. Announces Positive Preclinical Data Underscoring the Potential of Its DeltEx Gamma-Delta T Cells to Target and Kill Ovarian Cancer

IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals

In8bio Announces New Data At Ash Showing 100% of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of Inb-100

IN8bio Announces FDA Clearance to Initiate A Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma

IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting

IN8bio, Inc. Appoints Michael R. Bishop to Its Scientific Advisory Board